ZENECA's FOLATE ANALOG ZD1694 IS IN PHASE II
Executive Summary
ZENECA's FOLATE ANALOG ZD1694 IS IN PHASE II for treating breast, colorectal, hepatic, lung and ovarian cancers. ZD1694 is an exclusive inhibitor of thymidalate synthase, a key component in the growth of cancer cells. Zeneca said Phase II clinical trials began in early 1993, and Phase I data are in the process of being reviewed.